Circulating Biomarkers Market Strategies, Top Players, Growth, Analysis, and Forecast by 2034

Coverage: Circulating Biomarkers Market covers analysis By Product (Circulating DNA, Circulating Tumor Cells, Other); End User (Hospitals, Medical Research Center, Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024   |   Base Year: 2025   |   Forecast Period: 2026-2034
  • Report Date : Mar 2026
  • Report Code : TIPRE00015763
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Circulating Biomarkers Market Strategies, Top Players, Growth, Analysis, and Forecast by 2034
Report Date: Mar 2026   |   Report Code: TIPRE00015763
Buy Now
Page Updated: Jan 2025

The Circulating Biomarkers Market is anticipated to expand at a CAGR of 10.1% from 2026 to 2034. Market conditions continue to evolve, leading to new opportunities for stakeholders. The overall landscape reflects stable progress and long-term growth potential.

The Circulating Biomarkers Market report covers analysis By Product (Circulating DNA, Circulating Tumor Cells, Other); End User (Hospitals, Medical Research Center,Others ). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report Circulating Biomarkers Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Circulating Biomarkers Market Segmentation Product

  1. Circulating DNA
  2. Circulating Tumor Cells
  3. Other

End User

  1. Hospitals
  2. Medical Research Center

Customizee This Report To Suit Your Requirement

Get FREE CUSTOMIZATION

Circulating Biomarkers Market: Strategic Insights

circulating-biomarkers-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Circulating Biomarkers Market Growth Drivers

  1. Advancements in Non-Invasive Diagnostics: The growth of the circulating biomarkers market is significantly driven by advancements in non-invasive diagnostics. These biomarkers are increasingly recognized for their role in managing cancer and chronic diseases, leading to market expansion.
  2. Investment in Biomarker Discovery: Market trends show that there is a surge in investment directed toward biomarker discovery. Competitive analysis reveals that companies are focusing on increasing the specificity and detection capability of biomarkers, enhancing their market competitiveness.
  3. Cancer Incidence and Early Detection: The rising global incidence of cancers is driving demand for early detection solutions, which in turn accelerates market growth. Biomarkers play a critical role in personalized medicine, leading to better treatment outcomes and improved survival rates.

Circulating Biomarkers Market Future Trends

  1. Transformation in Cancer Diagnostics: Circulating biomarkers are revolutionizing liquid biopsy applications in cancer diagnostics. Key players in the market are heavily investing in developing new detection platforms to improve testing accuracy and speed, positioning themselves for long-term growth.
  2. Innovations in Profiling Technologies: Recent innovations in profiling technologies are enabling more accurate and reliable tests for circulating biomarkers. These advancements are shaping market dynamics by enhancing the detection capabilities and defining strategies for the industry's future growth.
  3. Opportunities in Personalized Medicine: SWOT analysis highlights significant opportunities in personalized medicine. Circulating biomarkers are becoming essential in targeted therapeutic interventions and precision health monitoring. As personalized medicine continues to grow, the market for circulating biomarkers is poised for substantial growth, especially with an increasing focus on individual health profiles and treatments.

Circulating Biomarkers Market Opportunities

  1. Non-Invasive Liquid Biopsies: Liquid biopsies are gaining traction due to their non-invasive nature, which makes them more widely accepted in medical diagnostics. The ease and efficiency of circulating biomarker testing are accelerating their adoption, especially in North America and Europe, where there are growing opportunities for innovative solutions in oncology.
  2. Oncology Studies and Market Expansion: The increasing focus on oncology research and studies is driving the demand for circulating biomarkers. Companies specializing in cancer diagnostics are playing a key role in defining the market landscape. As a result, there are significant opportunities to reach untapped markets in the Asia-Pacific region, where demand for advanced cancer diagnostic solutions is growing.
  3. Collaborations and Strategic Partnerships: The development of circulating biomarkers is heavily influenced by strategic partnerships with universities and research institutions. These collaborations enhance the R&D capabilities of companies and allow for geographical expansion, especially into emerging regions. This approach not only improves the market share of key players but also accelerates innovation and strengthens their position in the global marketplace.
Circulating Biomarkers Market Regional Insights

The regional trends and factors influencing the Circulating Biomarkers Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Circulating Biomarkers Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Circulating Biomarkers Market Report Scope

Report Attribute Details
Market size in 2025 US$ XX Million
Market Size by 2034 US$ XX Million
Global CAGR (2026 - 2034) 10.1%
Historical Data 2021-2024
Forecast period 2026-2034
Segments Covered By Product
  • Circulating DNA
  • Circulating Tumor Cells
  • Other
By End User
  • Hospitals
  • Medical Research Center
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • GE Healthcare
  • Agilent Technologies
  • Epigenomics AG
  • Fluxion Biosciences
  • Affymetrix
  • BD
  • Abbott Laboratories
  • Biocept

Circulating Biomarkers Market Players Density: Understanding Its Impact on Business Dynamics

The Circulating Biomarkers Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.


circulating-biomarkers-market-cagr

  • Get the Circulating Biomarkers Market top key players overview

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Circulating Biomarkers Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Circulating Biomarkers Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Key companies of this market are: GE Healthcare, Agilent Technologies, Epigenomics AG, Fluxion Biosciences, Affymetrix, BD, Abbott Laboratories, Biocept.

Key future trends in this market are - Rising Adoption in Liquid Biopsy, Advances in Biomarker Profiling Technologies, Expanding Role in Personalized Medicine

The Circulating Biomarkers Market is estimated to witness a CAGR of 10.1% from 2026 to 2034.

The major factors driving the market are: Shift toward liquid biopsies, Advancements in genomics and proteomics, Increasing cancer prevalence
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Our Clients
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Email: sales@theinsightpartners.com
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
GDPR
CCPA